20 minute delayed data provided by Yahoo. Adeona Pharmaceuticals makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

Adeona Pharmaceuticals, Inc. is a company dedicated to the awareness, diagnosis, prevention and treatment of subclinical zinc deficiency and chronic copper toxicity in the mature population. Adeona believes that such conditions may contribute to the progression of debilitating degenerative diseases, including, Dry Age-Related Macular Degeneration (Dry AMD), Alzheimer's disease (AD) and mild cognitive impairment (MCI) in susceptible persons. Adeona is also developing a number of late-stage clinical drug candidates for the treatment of rheumatoid arthritis and multiple sclerosis. Read More»

Current Product Pipeline:

Zinthionein:

Zinthionein Timeline

Dry AMD

We are developing Zinthionein™ (oral zincmonocysteine), an orally active compound for the treatment of dry age-related macular degeneration (AMD). Oral ZMC the activity of antioxidant enzymes catalase and glutathione peroxidase, and the antioxidant protein metallothionein in cultured retinal pigment epithelial cells more efficiently and potently than currently available zinc formulations. These complexes are the subject of a recently issued U.S. Patent covering its composition of matter and a patent application and various uses thereof. Zinthionein™ has completed an 80 patient phase II clinical trial for the treatment of Dry AMD.
Read More»

Trimesta:

Trimesta Timeline

Relapsing Remitting Multiple Sclerosis

We are developing Trimestaª as an oral, immunomodulatory and anti-inflammatory agent for the North American market. Estriol has been approved and marketed throughout Europe and Asia as a mild estrogenic agent for over 40 years for the treatment of post-menopausal hot flashes.
Read More»

Effirma:

Oral ZMC Timeline

Fibromyalgia Syndrome

We are developing EFFIRMA (oral flupirtine), a novel, centrally-active, oral therapy for the treatment of fibromyalgia syndrome (FMS) and we plan to conduct a limited, controlled phase II proof-of-concept clinical trial in this indication. FMS is a common, centrally-mediated pain disorder characterized by chronic diffuse pain and other symptoms.
Read More»

Anti-CD4 802-2:

CD4 Inhibitors Timeline

Graft Vs. Host Disease

We are developing a series of rationally-designed, small molecule/peptidomimetic inhibitors of the T-cell CD4 co-receptor. The CD4 co-receptor is central to a number of autoimmune disorders such as MS. Our anti-CD4 molecules are designed to selectively block the dimerization and oligomerization of adjacent CD4 receptors via the D1 domains of such receptors.
Read More»

Oral dnaJP1:

Oral dnaJP1 Timeline

Rheumatoid Arthritis

Oral dnaJP1 is a once-daily epitope specific immunotherapy for rheumatoid arthritis (RA) patients. Oral dnaJP1 is a heat shock protein (hsp)-derived peptide which was previously identified as a contributor of T cell mediated inflammation in RA Immune responses to hsp are often found at sites of inflammation and have an initially amplifying effect that needs to be downregulated to prevent tissue damage. The mechanisms for this regulation involve T cells with regulatory function that are specific for hsp-derived antigens.
Read More»